Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly

1. Novo Nordisk aims to compete with Eli Lilly using UBT251 obesity drug. 2. UBT251 uses a three-pronged method for weight loss, enhancing efficacy. 3. Eli Lilly's retatrutide shows superior weight loss compared to UBT251. 4. Novo Nordisk's deal reflects ongoing competition in the obesity drug market. 5. Retatrutide results expected in 2025, giving Eli Lilly a head start.